December 12, 2019
Agencies announced they would begin to issue these licenses in 2016, delayed, and made a similar announcement again in 2019; "Evidence-based public policy is crucial to ensuring our marijuana laws best serve patients and health care providers"
Senators Request Update from Federal Agencies on Progress Towards Issuing Long-Delayed Licensing of Marijuana Manufacturing for Research Purposes
Agencies announced they would begin to issue these licenses in 2016, delayed, and made a similar announcement again in 2019; "Evidence-based public policy is crucial to ensuring our marijuana laws best serve patients and health care providers"
Washington, DC - United States Senators Elizabeth Warren
(D-Mass.), Ron Wyden (D-Ore.), Kamala Harris (D-Calif.), Kirsten Gillibrand
(D-N.Y.), Cory Booker (D-Conn.), Jeff Merkley (D-Ore.), Edward J. Markey
(D-Mass.), and Jacky Rosen (D-Nev.) sent a letter to the U.S. Department of
Health and Human Services (HHS), the Drug Enforcement Administration (DEA), and
the White House Office of National Drug Control Policy (ONDCP), requesting an
update on the progress of the federal government's efforts to facilitate
research on medical marijuana by issuing needed manufacturing licenses. The
senators seek guidance on how the DEA will make these licenses available to
qualified researchers in a timely manner given that the federal government has
a unique responsibility to coordinate medical marijuana research efforts -- and
has delayed
issuing these licenses in the past.
"With millions of American adults having access to recreational
marijuana and a growing number seeking the drug for medicinal purposes, the
federal government is not providing the necessary leadership and tools in this
developing field," wrote the lawmakers.
"Evidence-based public policy is crucial to ensuring our marijuana laws
best serve patients and health care providers."
The lawmakers have requested responses no later than January 10, 2020, to
better understand both the DEA's decision-making, and its work with HHS and
ONDCP to expand medical marijuana research.
"This research is crucial to developing a thorough understanding of
medical marijuana and would be invaluable to doctors, patients, and lawmakers
across the nation," wrote the lawmakers.
Senator Warren led similar letters to the agencies in July
2015, December
2015, and June
2016 requesting information on their efforts to facilitate government
research on marijuana, highlighting the need for the federal government's need
to take leadership and encourage cannabis research and to issue additional
licenses for production for such purposes. Senator Warren has also called
for the rescheduling of marijuana.
###
Next Article Previous Article